# US 11,439,698 B2 · Toxoid preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,698 B2
- Document ID: US11439698B2
- Status: Granted
- Kind: B2
- Application number: 15/679,096
- Filed: 2017-08-16
- Published: 2017-12-28
- Granted: 2022-09-13
- Earliest claimed: 2013-12-02
- Assignees: Arytha Biosciences, LLC
- Applicants: Arytha Biosciences, LLC
- Inventors: Che-Ming Jack Hu
- Web page: https://patentgrep.com/patent/US11439698B2

## CPC

- A61K 39/107: {Vibrio}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 39/0283: {Shigella}
- A61K 39/085: Staphylococcus
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.

## Claims

### Claim 1

An immunogenic composition comprising an effective amount of a liposome and an immunogenic adjuvant or immunopotentiator, and
wherein said liposome comprises synthetic lipid bilayers and a pore-forming toxin absorbed in said synthetic lipid bilayers of said liposome, wherein:
said synthetic lipid bilayers comprise sphingomyelin,
said pore-forming toxin is alpha hemolysin of Staphylococcus aureus or an animal pore-forming toxin,
said synthetic lipid bilayers further comprise a synthetic lipid that is selected from the group consisting of phosphotidylcholine, phosphotidylethanolamine, phosphatidylinositol and phosphotidylserine,
said liposome has at least one dimension between about 1 nm and about 150 nm,
said liposome does not comprise a solid inner core, and
said pore-forming toxin substantially retains its natural structural integrity for eliciting an immune response to a natural pore-forming toxin.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the liposome substantially retains the pore-forming toxin.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the pore-forming toxin is alpha hemolysin of Staphylococcus aureus.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, further comprising another active ingredient.

### Claim 5 (depends on 1)

A vaccine comprising the immunogenic composition of claim 1.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein the liposome is configured to allow the pore-forming toxin to be processed in an endolysosomal compartment.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein the synthetic lipid bilayers comprise a synthetic lipid that is selected from the group consisting of phosphotidylethanolamine, phosphatidylinositol, and phosphotidylserine.